Patents by Inventor Jon A. Wolff

Jon A. Wolff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7816337
    Abstract: Described is a process for delivering a biologically active compound to a cell by reversibly linking the compound to a membrane active polymer. In particular, polymer-polynucleotide conjugates are described. Methods for reversibly modifying the polymers to decrease cellular toxicity and improve efficacy are provided.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: October 19, 2010
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren Wakefield, Jon A Wolff, Kirk Ekena, James E. Hagstrom
  • Patent number: 7803782
    Abstract: An intravenous delivery method is described that enables delivery of polynucleotides to extravascular cells of a mammalian limb. The method involves the injection of polynucleotides into a distal vein of a limb that is transiently occluded. Polynucleotide delivery is facilitated by rapid injection in sufficient volume to enable extravasation of the solution into surrounding tissue.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: September 28, 2010
    Assignee: Roche Madison Inc.
    Inventors: James E. Hagstrom, Julia Hegge, Hans Herweijer, Jon A. Wolff
  • Patent number: 7781415
    Abstract: A process for delivering a polynucleotide to a cardiac tissue cell in a mammal is described, comprising introducing a composition consisting of a polynucleotide into a blood vessel and increasing permeability of the blood vessel to the polynucleotide. The polynucleotide can be a small interfering RNA or microRNA and inhibit gene expression in the cell.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: August 24, 2010
    Assignee: Roche Madison Inc.
    Inventors: Hans Herweijer, Julia Hegge, Jon A. Wolff, David L. Lewis
  • Publication number: 20100004180
    Abstract: The present invention relates to the identification and use of peptide and peptide analogs that represent epitopes for naturally-occurring antibodies (Nabs). These epitopes may be used to monitor the degree of autoimmunity in an organism, as well as to modulate the activity of B-cells producing Nabs.
    Type: Application
    Filed: April 29, 2009
    Publication date: January 7, 2010
    Inventors: Jon A. Wolff, Alex V. Sokoloff
  • Patent number: 7642248
    Abstract: A process is described for the delivery of a therapeutic polynucleotide to limb muscle tissue suffering from or potentially suffering from Muscular Dystrophy. The polynucleotide is inserted into a mammalian limb vessel such as an artery. Delivery efficiency and distribution is enhanced by combining injection of a solution containing the polynucleotide with the use of an externally applied cuff.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: January 5, 2010
    Assignee: Roche Madison Inc
    Inventors: Vladimir G. Budker, Jon A. Wolff
  • Patent number: 7601367
    Abstract: Described is a deliverable composition with low toxicity comprising an amphipathic compound, a polycation, and a siRNA. The composition may be used in the process of delivering a siRNA to an animal cell or more particularly, a mammal cell.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: October 13, 2009
    Assignee: Mirus Bio LLC
    Inventors: Sean D. Monahan, David L. Lewis, Hans Herweijer, Jon A. Wolff, James E. Hagstrom, Aaron G. Loomis, Vladimir Trubetskoy, Lori Higgs
  • Patent number: 7589059
    Abstract: Disclosed is a system for providing in vivo delivery of molecules or complexes to extravascular mammalian cells using an intravascular administration route. The molecules or complexes are inserted in an injection solution into a mammalian vasculature. Insertion of the injection solution at an appropriate rate transiently increases the volume of extravascular fluid in the tissue thereby facilitating delivery of the molecule to the cell.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: September 15, 2009
    Assignee: Roche Madison Inc.
    Inventors: Jon A. Wolff, Vladimir G. Budker, Hans Herweijer, James E. Hagstrom, Sean D. Monahan, Julia Hegge, Vladimir Subbotin
  • Patent number: 7547683
    Abstract: Processes are described for obtaining high levels of gene expression in primates after injection of nucleic acid to the liver via the lumen of the hepatic vein. The described process results in high level of gene expression with transient increases in liver enzymes.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: June 16, 2009
    Assignee: Roche Madison, Inc.
    Inventors: Jon A. Wolff, Tatyana Budker, legal representative, Julia Hegge, James E. Hagstrom, Vladimir G. Budker
  • Patent number: 7524680
    Abstract: An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: April 28, 2009
    Assignee: Roche Madison Inc.
    Inventors: Jon A. Wolff, James E. Hagstrom, Vladimir G. Budker, Vladimir S. Trubetskoy
  • Patent number: 7507722
    Abstract: Disclosed is a process for transfecting genetic material into a mammalian cell to alter endogenous properties of the cell. The process comprises designing a polynucleotide for transfection. Then the polynucleotide is inserted into a mammalian blood vessel. Prior to insertion, subsequent to insertion, or concurrent with insertion the permeability of the vessel is increased using an exterior cuff thereby the genetic material is delivered to the parenchymal cell.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: March 24, 2009
    Assignee: Roche Madison Inc.
    Inventors: Jon A. Wolff, Vladimir G. Budker
  • Patent number: 7501394
    Abstract: We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: March 10, 2009
    Assignee: Roche Madison Inc.
    Inventors: Alexander V. Sokoloff, So Wong, Jon A. Wolff, Sean D. Monahan, James Ludtke, Lori Higgs, Darren H. Wakefield, Magdolna G. SebestyƩn
  • Publication number: 20090048410
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: February 19, 2009
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, James E. Hagstrom
  • Patent number: 7491538
    Abstract: A process and compound wherein nucleic acids can be modified with a host of molecules and maintain their ability to be expressed. A modifying chemical attachment of polyions to polynucleotides can be used to facilitate the change of tertiary structure of the nucleic acid and in some cases condensation of nucleic acids into smaller, charged particles useful in delivering the nucleic acid to a cell.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: February 17, 2009
    Assignee: Mirus Bio LLC
    Inventors: Jon A. Wolff, Vladimir G. Budker, James E. Hagstrom, Paul M. Slattum
  • Patent number: 7482160
    Abstract: A method of forming polymers in the presence of nucleic acid using template polymerization. These methods can be used for the delivery of nucleic acids, for condensing the nucleic acid, for forming nucleic acid binding polymers, for forming supramolecular complexes containing nucleic acid and polymer, and for forming an interpolyelectrolyte complex.
    Type: Grant
    Filed: December 30, 2005
    Date of Patent: January 27, 2009
    Assignee: Roche Madison Inc.
    Inventors: Sean D. Monahan, David B. Rozema, Vladimir Trubetskoy, Paul M. Slattum, Jon A. Wolff, Vladimir G. Budker, James E. Hagstrom, Lisa J. Hanson
  • Publication number: 20090023890
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: January 22, 2009
    Inventors: Sean D. Monahan, Darren H. Wakefield, David B. Rozema, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Patent number: 7473419
    Abstract: Disclosed is a process for providing for expression of an exogenous nucleic acid in an extravascular parenchymal cell of a mammal. The nucleic acid is inserted into a vessel of a mammal and the permeability of the vessel is increased. Increasing permeability of the vessel allows delivery of the nucleic acid to an extravascular parenchymal cell.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: January 6, 2009
    Assignee: Roche Madison Inc.
    Inventors: Jon A. Wolff, James E. Hagstrom, Hans Herweijer, Vladimir G. Budker, Julia Hegge
  • Patent number: 7470539
    Abstract: Polyampholyte are able to condense nucleic acid to form small complexes which can be utilized in the delivery of nucleic acid to mammalian cells. The polyampholytes can be formed prior to interaction with nucleic acid or they can be formed in the presence of nucleic acid. Stabilized polycation/nucleic acid complexes can be modified to reduce the positive charge of the polycation and add targeting ligands without destabilizing the complex. The resultant particles retain their small size and are more effective in delivery of nucleic acid to cells in vivo.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: December 30, 2008
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, Vladimir Trubetskoy, James E. Hagstrom, Vladimir G. Budker, Jason Klein, So Wong
  • Publication number: 20080287630
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 20, 2008
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080287628
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 20, 2008
    Inventors: David B. Rozema, Darren H. Wakefield, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080281041
    Abstract: The present invention is directed to reversibly inactivation of membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: November 13, 2008
    Inventors: David B. Rozema, Darren H. Wakefield, Jon A. Wolff, James E. Hagstrom